These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 7882653

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
    Brosman SA.
    Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 5. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
    Jakse G.
    Wien Klin Wochenschr; 1987 Feb 20; 99(4):114-8. PubMed ID: 3577186
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intravesical bacillus Calmette-Guérin (BCG) in superficial bladder tumors. An overview.
    Debruyne FM, Witjes JA, vd Meijden AP.
    Arch Esp Urol; 1990 Feb 20; 43 Suppl 2():133-8. PubMed ID: 2096774
    [No Abstract] [Full Text] [Related]

  • 8. Reactive arthritis associated with bacillus Calmette-Guérin immunotherapy for carcinoma of the bladder: immune reactivity against mycobacterial antigens.
    Miossec P.
    J Rheumatol; 1996 Aug 20; 23(8):1485. PubMed ID: 8856640
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.
    Lamm DL.
    Clin Infect Dis; 2000 Sep 20; 31 Suppl 3():S86-90. PubMed ID: 11010830
    [Abstract] [Full Text] [Related]

  • 11. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
    Catalona WJ, Ratliff TL.
    Surg Annu; 1990 Sep 20; 22():363-78. PubMed ID: 2408170
    [No Abstract] [Full Text] [Related]

  • 12. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
    Palou J, Laguna P, Millán-Rodríguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodríguez J.
    J Urol; 2001 May 20; 165(5):1488-91. PubMed ID: 11342902
    [Abstract] [Full Text] [Related]

  • 13. BCG for bladder cancer.
    Med Lett Drugs Ther; 1991 Apr 05; 33(841):29-30. PubMed ID: 2002783
    [No Abstract] [Full Text] [Related]

  • 14. The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer.
    Brosman SA, Lamm DL.
    J Urol; 1990 Aug 05; 144(2 Pt 1):313-5. PubMed ID: 2374197
    [Abstract] [Full Text] [Related]

  • 15. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
    Palou J, Xavier B, Laguna P, Montlleó M, Vicente J.
    Urology; 1996 Apr 05; 47(4):482-4. PubMed ID: 8638354
    [Abstract] [Full Text] [Related]

  • 16. Miliary tuberculosis of the lung in a patient treated with bacillus Calmette-Guerin for superficial bladder cancer.
    Iantorno R, Nicolai M, Storto ML, Ciccotosto C, Cipollone G, Mastroprimiano G, Tenaglia RL.
    J Urol; 1998 May 05; 159(5):1639-40. PubMed ID: 9554372
    [No Abstract] [Full Text] [Related]

  • 17. Complications of bacillus Calmette-Guérin immunotherapy.
    Lamm DL.
    Urol Clin North Am; 1992 Aug 05; 19(3):565-72. PubMed ID: 1636240
    [Abstract] [Full Text] [Related]

  • 18. [Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report].
    Shiba M, Fujii T, Takatera H.
    Hinyokika Kiyo; 2003 Oct 05; 49(10):599-601. PubMed ID: 14655604
    [Abstract] [Full Text] [Related]

  • 19. [Squamous cell carcinoma of the urinary bladder after intravesical bacillus Calmette-Guerin therapy for carcinoma in situ: a case report].
    Uemura M, Nishimura K, Nakagawa M, Kanno N, Miyoshi S, Kawano K, Inoue H.
    Hinyokika Kiyo; 2004 Nov 05; 50(11):809-11. PubMed ID: 15628544
    [Abstract] [Full Text] [Related]

  • 20. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
    Witjes JA, Fransen MP, van der Meijden AP, Doesburg WH, Debruyne FM.
    Urol Int; 1993 Nov 05; 51(2):67-72. PubMed ID: 8351757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.